Chemocentryx, Inc.

Solomon Ungashe

Sreenivas Punna

Yibin Zeng

Trevor T Charvat

Andrew M K Pennell

Zheng Wei

John Jessen Wright

Antoni Krasinski

Anita Melikian

Andrew Pennell

Qiang Wang

Cheng Hu

William L Thomas

Aaron Robert Novack

Edward J Sullivan

Jeff Jin

Jay Patrick Powers

Wei Yu Chen

Daniel J Dairaghi

Jimmie L Moore

Derek Hansen

Arindrajit Basak

Penglie Zhang

Thomas J Schall

Brett Permack

Andrew Mk Pennell

J J Wright

Xuefei Tan

Manmohan Reddy Leleti

Christopher W Lange

Yandong Li

Hiufung Chu

Timothy J Sullivan

William D Thomas

Aaron Novack

Anita Melikan

Jimmie Moore

Daniel Dairaghi

Andrew MK Pennell

M K Andrew Pennell

Arindrajit Badak

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

Heteroaryl sulfonamides and CCR2/CCR9

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists. 

Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation

Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Aryl sulfonamides

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides

A novel crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy -pyridine-4-carbonyl)-phenyl]-benzenesulfonamide and pharmaceutical compositions containing the same are disclosed. Processes for the preparation thereof and methods for use thereof are also disclosed.

Crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides

Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.

Pyrrolidinone carboxamide derivatives

Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

Bis-aryl sulfonamides

Fused heteroaryl pyridyl benzenesulfonamides are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.

Growing community of inventors

Fremont, CA, United States of America

Solomon Ungashe